Pruritus Therapeutics Market Size, Share, Growth & Trends 2028

The global Pruritus Therapeutics Market accrued earnings worth approximately 10.1 (USD Billion) in 2021 and is predicted to gain revenue of about 22.30 (USD Billion) by 2028, is set to record a CAGR of nearly 4.9% over the period from 2022 to 2028. The study provides assessment and analysis of the Pruritus Therapeutics Market on a global & regional level. It offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2021 along with a forecast from 2022 to 2028 based on revenue (USD Billion).

Request Free Sample

Pruritus Therapeutics Market: Overview

Pruritus is an unpleasant sensation and a most common skin disease symptom leading an individual to scratch skin. It is a cutaneous symptom and if it is ignored can lead to chronic pain as well as severely impact quality of life. For instance, pruritus can cause sleep disturbance, anxiety, and attention-deficit or hyperactivity disorder. Furthermore, if left untreated it can cause psychiatric and systemic ailments. According to NIH researchers, studies have revealed that hemodialysis individuals prone to more itching have more probability that their lifespan can be reduced.

Furthermore, chronic pruritus, which is one of key dermatology symptoms, is intractable and has huge impact on quality of life. Apart from this, the ailment is associated with psychological, systemic, and neurologic disorders. As per reports, pathogenesis of chronic pruritus is acute and can result in inflammation in cell tissues. Additionally, increase in knowledge of chronic pruritus pathogenesis coupled with access to high quality data from clinical experiments has resulted in emergence of new therapies for treating pruritus. These drug treatments are also anticipated to be utilized in routine dermatology medical practice.  They are opioidergic medicines such as kappa-opioid agonists & mu-opioid antagonists, Janus Kinase inhibitors, neurokinin-1 receptor antagonists, biologic medicines, histamine H4 receptor antagonists, ileal bile acid transport inhibitors, and aryl hydrocarbon receptor agonists.

Request Free Sample

Pruritus Therapeutics Market: Growth Drivers

Rise in occurrence of skin itching symptoms causing psoriasis, dermatitis, and urticarial will drive pruritus therapeutics market growth. In addition to this, high unmet healthcare requirements and launching of novel products including Bilastine and REMITECH drugs are predicted to contribute majorly towards market profits. Low drug costs and willingness of subjects to take treatment will prompt expansion of industry in next few years. High opportunity costs for treating skin diseases such as psoriasis will proliferate expansion of pruritus therapeutics industry over ensuing years.

In addition to this, large-scale use of barrier repair creams, moisturizers, and emollients is a key to pruritus treatment and helps in minimizing pruritus with help of enhanced barrier activities. Furthermore, topical corticosteroids are utilized for providing relief to patients having itching sensations and inflammatory skin ailments including psoriasis. However, topical calcineurin inhibitors, pimecrolimus, and tacrolimus have proved to be effective in alleviating pruritus in subjects suffering from atopic dermatitis. Additionally, azathioprine, doxepins, cyclosporine, oral antihistamines, menthol, capsaicin, topical salicylic acid, neuroleptics, aprepitant, and topical cannabinoids have proved effective in treatment of pruritus. All these aforementioned aspects will result in enlarged expansion of pruritus therapeutics market. Clinical studies have proved that drugs such as NGX-100, TS-022, and Methylnaltrexone have huge potential of effectively treating pruritus, thereby steering market trends.

Pruritus is the medical term for itchy skin. Pruritus is the most common dermatological disorder. Pruritus is a normal body reaction to protect from harmful external parasites or substances such as insect bites. However, it can be as a result of wide range of skin diseases. Pruritus lasting for more than 6 weeks is called chronic pruritus. Pruritus has been classified into the following four key types include neuropathic, cutaneous, psychogenic and neurogenic. Chronic renal failure is a vital cause of persistent pruritus. Pruritus is enhanced or provoked by a number of chemical substances such as prostaglandins, cytokines, histamine, proteases, neuropeptides and bile salts. Furthermore, chronic pruritus is becoming a burden to society mainly due to the treatment-related costs, which is particularly high due to the elevation rate of therapeutic failure.

Report Scope:

Pruritus Therapeutics Market: Regional Landscape

North America To Account Majorly Towards Regional Market Share By 2028

Growth of regional market over forecasting timeline can be credited to launching of new therapeutic products and approval of generic medicines by U.S. FDA for treating pruritus & chronic pruritus such as psoriasis. Apart from this, supportive government regulations pertaining to pruritus treatment will spur regional market surge. According to NIH researchers, in 2011, occurrence of psoriasis in the U.S. was nearly 20% in children and about 4% in grown-ups.

Pruritus Therapeutics Market: Competitive Landscape

Key players influencing market growth and included in report are :

• Brunswick Corporation
• Precor Incorporated
• Johnson Health Tech Co. Ltd.
• Technogym
• Nautilus Strength
• Icon Health & Fitness
• Amer Sports Oyji
• Cybex International Inc.

The global Pruritus Therapeutics Market is segmented as follows:

By Product

• Corticosteroids

• Antihistamines
• Local Anesthetics
• Counterirritants
• Immunosuppressant
• Calcineurin Inhibitors

By Disease Type

• Atopic Dermatitis

• Allergic Contact Dermatitis
• Urticaria

By Region

• North America

  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa